Kings Point Capital Management’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-400
Closed -$40K 514
2019
Q3
$40K Hold
400
0.01% 326
2019
Q2
$37K Hold
400
0.01% 292
2019
Q1
$38K Hold
400
0.01% 259
2018
Q4
$26K Sell
400
-2,000
-83% -$148K 0.01% 288
2018
Q3
$215K Hold
2,400
0.04% 141
2018
Q2
$191K Hold
2,400
0.04% 145
2018
Q1
$214K Buy
2,400
+400
+20% +$38.4K 0.04% 137
2017
Q4
$209K Sell
2,000
-400
-17% -$45.1K 0.04% 141
2017
Q3
$350K Buy
2,400
+400
+20% +$54.5K 0.08% 125
2017
Q2
$260K Hold
2,000
0.06% 128
2017
Q1
$249K Buy
2,000
+1,000
+100% +$120K 0.06% 127
2016
Q4
$116K Hold
1,000
0.03% 154
2016
Q3
$105K Sell
1,000
-316
-24% -$34.2K 0.03% 148
2016
Q2
$130K Hold
1,316
0.03% 137
2016
Q1
$132K Buy
1,316
+22
+2% +$2.27K 0.03% 131
2015
Q4
$155K Hold
1,294
0.04% 129
2015
Q3
$140K Hold
1,294
0.04% 148
2015
Q2
$150K Hold
1,294
0.04% 143
2015
Q1
$149K Hold
1,294
0.04% 143
2014
Q4
$145K Buy
1,294
+294
+29% +$31K 0.04% 131
2014
Q3
$95K Hold
1,000
0.03% 144
2014
Q2
$86K Hold
1,000
0.03% 148
2014
Q1
$70K Buy
+1,000
New +$79.2K 0.02% 146

Other funds holding CELG

Kings Point Capital Management's CELG Position: Q4 2019 in Review

Kings Point Capital Management sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 400 shares — an estimated $40K sold.

Kings Point Capital Management first reported a position in CELG in Q1 2014 and held it in 23 quarters. The position peaked at $350K in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Kings Point Capital Management reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Kings Point Capital Management sold 400 Celgene Corp shares in Q4 2019, an estimated $40K.
  • Kings Point Capital Management first reported a position in Celgene Corp in Q1 2014 and held it in 23 quarters.
  • Kings Point Capital Management's Celgene Corp position peaked at $350K in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Kings Point Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.